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Introduction
Sildenaﬁl citrate (VIAGRA
 , Pﬁzer Limited, Sand-
wich, Kent, UK), approved by the United States
Food and Drug Administration in March 1998 and
by the European Medicines Agency in September
1998 for the on-demand treatment of erectile dys-
function (ED), was the ﬁrst phosphodiesterase type 5
(PDE5) inhibitor licensed for this indication. Initial
clinical trials of sildenaﬁl were conducted in the
United Kingdom (1), Europe (2) and the United
States (3) and were followed by trials performed in
Central and South America (4–6), Africa (7,8), Asia
(9,10) and Australia (11). The effectiveness and
safety of sildenaﬁl for treating ED have been estab-
lished in over 120 manufacturer-sponsored clinical
trials with a cumulative exposure of more than
14,000 patient-years and in other independent stud-
ies (12,13). In most of the trials, sildenaﬁl was
administered on demand with a starting dose of
50 mg and subsequent adjustment to 25 mg or,
more usually, 100 mg depending on toleration and
efﬁcacy, but it has also been studied in once-daily
dosage (10, 25 and 50 mg) (14) and in single-doses
up to 800 mg (15). Comprehensive reviews examin-
ing the efﬁcacy and safety proﬁle of sildenaﬁl have
been published (16,17). As of August 2008, sildenaﬁl
had been prescribed to more than 37 million men,
and more than a billion tablets (averaging six per
second) have been dispensed worldwide (18).
Treatment-related adverse events with PDE5 inhib-
itors such as sildenaﬁl, vardenaﬁl (Levitra
 , Bayer
AG, Leverkusen, Germany) and tadalaﬁl (Cialis
 ,
Eli Lilly Nederland B.V., Houten, the Netherlands)
are generally mild to moderate, showing minor
differences across the PDE5 inhibitor class (19,20).
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SUMMARY
Aim: To review special safety topics associated with sildenaﬁl and to document
the tolerability of 50- and 100-mg doses, overall and by age, in men with erectile
dysfunction (ED). Methods: Data were collated from 67 double-blind placebo-
controlled (DBPC) trials (> 14,000 men) conducted by the manufacturer and from
the manufacturer’s postmarketing safety database (39,277 patients). The DBPC
data were stratiﬁed by dose, starting dose and age (‡ 65 and ‡ 75 years). Special
safety topics included cardiovascular risk, priapism, non-arteritic anterior ischaemic
optic neuropathy (NAION), impaired renal and hepatic function, drug interactions
(i.e. nitrates, cytochrome P3A4 inhibitors, other ED therapies and a-blockers) and
incorrect use. Results: Sildenaﬁl was well tolerated at a dose of 50 or 100 mg in
men with ED, overall, in those aged ‡ 65 years, and in those aged ‡ 75 years.
Analyses of the databases did not reveal any causal link between sildenaﬁl and
cardiovascular events, or any new safety risks relating to cardiovascular events, pri-
apism, NAION, hearing loss or drug interactions. In the small number of men with
moderate impairment of renal function or hepatic function who were treated with
sildenaﬁl in DBPC trials, the safety proﬁle was similar to that in men with no
impairment of renal or hepatic function. Overdose with sildenaﬁl was rare in the
ED population. No new safety issues, emerging trends or adverse reactions were
identiﬁed in conjunction with overdose, dependence, abuse or misuse. Conclu-
sion: This collated review conﬁrms generally the good tolerability and established
safety proﬁle of sildenaﬁl 50 and 100 mg in men with ED and reveals no new
safety issues.
Review Criteria
Using a database of 67 double-blind placebo-
controlled trials conducted by the manufacturer and
the manufacturer’s postmarketing safety database,
we reviewed special safety topics and, for the most
frequently prescribed doses (50 and 100 mg),
conducted a comprehensive assessment of the
tolerability of sildenaﬁl overall and by age (i.e.
stratifying cut-offs of ‡ 65 and ‡ 75 years).
Message for the Clinic
Sildenaﬁl 50 and 100 mg were generally well
tolerated, including by elderly men. There was no
causal link with cardiovascular events. Furthermore,
no new safety risks relating to priapism, non-
arteritic anterior ischaemic optic neuropathy or
incorrect use were detected. In addition, there were
no unexpected adverse reactions from drug
interactions, and a similar safety proﬁle was
present in men with or without moderate
impairment of renal or hepatic function.
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240 doi: 10.1111/j.1742-1241.2009.02254.xHeadache, facial ﬂushing, nasal congestion and dys-
pepsia are the most common adverse events (19,21–
23). Postmarketing surveillance of PDE5 inhibitors
has provided additional data that, in general, indicate
a safety proﬁle consistent with that reported in pre-
marketing clinical studies (24–30). However, there
are some gaps in the knowledge base. For example,
the safety of PDE5 inhibitor therapy has not previ-
ously been reported by age,
1 despite an increased
prevalence of ED in older men (31). Given the age-
ing populations of the developed and developing
world, with an expected increase in the prevalence of
ED to more than 300 million men worldwide by
2025 (32), this will become increasingly important.
Using a database of all 67 of the manufacturer’s
double-blind placebo-controlled (DBPC) trials and
the manufacturer’s postmarketing safety database, we
conducted a comprehensive assessment of the tolera-
bility of sildenaﬁl overall, by dose and by age (cut-
offs of ‡ 65 and ‡ 75 years). The objective of this
collated review was to assess special safety topics and
to document the tolerability by age of the most
frequently prescribed doses (50 and 100 mg).
2
Methods
DBPC database
The DBPC database contains all routine safety data
and serious adverse event data for the 67 DBPC sil-
denaﬁl trials for the indication of ED, which were
completed by June 1, 2007. Appropriate Institutional
Review Board approval and patient informed consent
were obtained for all trials.
Although sildenaﬁl was studied in doses of up to
800 mg in phase I, single-dose, healthy volunteer
studies (15), doses in the DBPC database ranged
from 5 to 200 mg. However, most of the trials used
the currently approved doses for the treatment of ED
(25, 50 and 100 mg) and included a double-blind
phase of 12 weeks (15). In 45 trials, the dose was
ﬂexible (most had dose adjustment at an interim
visit according to efﬁcacy and toleration while blind-
ing was maintained), and in 22 trials, the dose was
ﬁxed. In most of the ﬂexible-dose trials, the initial
dose of sildenaﬁl was 50 mg and most patients were
titrated to 100 mg. In nearly all of the trials, sildena-
ﬁl could be taken on demand approximately 1 h
before sexual activity but not more than once daily.
Many of the trials also included an open-label exten-
sion phase after the completion of the DBPC phase,
in which most patients used sildenaﬁl 100 mg.
Participants were generally required to have a doc-
umented history of ED of at least 3–6 months and to
be in a stable sexual relationship. Trials that investi-
gated conditions that contribute to the aetiology of
ED generally required that the condition (e.g. diabe-
tes mellitus) be stable or stable under treatment.
Otherwise, the inclusion and exclusion criteria of the
trials were broadly consistent with the Viagra pre-
scribing information (15). In most of the trials, men
receiving nitrate therapy and nitric oxide donors
were excluded but, in some early trials, a few men
randomised to sildenaﬁl (n = 16) or placebo (n =9 )
were taking glyceryl trinitrate ‘as required’. In some
of the more recent trials, to avoid potential hypoten-
sion, any patient who was currently prescribed,
taking, and⁄or likely to be treated with an a-blocker
was either excluded from entering the trial or was
not to take study medication within 4 h of dosing
with the a-blocker.
There were no restrictions on other vasoactive and
antihypertensive medications. Men with severe
cardiac failure, unstable angina or a recent history
(i.e. within 3–6 months) of stroke or myocardial
infarction were excluded. Otherwise, efﬁcacy and
safety were assessed in men with a variety of comor-
bid conditions that share risk factors with ED,
including diabetes mellitus, hypertension, cardio-
vascular disease (coronary artery disease, angina,
myocardial infarction and stroke), radical prostatec-
tomy, spinal cord injury and depression.
Postmarketing safety database
From ﬁrst launch in 1998 through September 2007
(when the database was closed), > 35 million
patients are estimated to have used sildenaﬁl world-
wide for the treatment of ED. In accordance with
Pﬁzer Pharmacovigilance Standard Operating Proce-
dures, the postmarketing safety database contains all
cases of adverse events that were reported spontane-
ously to Pﬁzer by healthcare professionals, persons
other than healthcare professionals, national or local
registries (when applicable) and health authorities, or
that are systematically identiﬁed from the medical
literature. It excludes cases from the sildenaﬁl clinical
trials programme (except for cases of serious adverse
events). It also excludes cases representative of silde-
naﬁl indications other than ED (i.e. pulmonary
hypertension). For cases reporting a dose, the dose
represents the ﬁrst daily dose taken by the patient at
the onset of an adverse event.
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1PubMed search: ‘erectile dysfunction’ (Mesh) and ‘drug toxicity’ (Mesh) and
(sildenaﬁl or vardenaﬁl or tadalaﬁl) and [‘age factors’ (Mesh) or ‘age groups’
(Mesh)].
2The recommended starting dose is 50 mg taken as needed approximately 1 h
before sexual activity [VIAGRA
  (sildenaﬁl citrate) summary of product
characteristics, http: ⁄⁄ www.emea.europa.eu ⁄ humandocs ⁄ PDFs ⁄ EPAR ⁄ viagra ⁄
H-202-PI-en.pdf]. Based on efﬁcacy and toleration, the dose may be increased to
100 mg or decreased to 25 mg. The maximum recommended dose is 100 mg. The
maximum recommended dosing frequency is once per day.
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In the clinical trials included in the DBPC database,
the severity of each adverse event was categorised
according to investigator judgment as mild (usually
transient, required no special treatment and did not
interfere with daily activities), moderate (low level of
inconvenience and may have interfered with daily
activities; usually ameliorated by simple therapeutic
measures), or severe (interrupted daily activity and
required systemic drug therapy or other medical
treatment). A serious adverse event was deﬁned as
any untoward medical occurrence that resulted in
death, was life threatening, required inpatient hospi-
talisation or prolongation of existing hospitalisation,
or resulted in a persistent or signiﬁcant disability⁄
incapacity or a congenital anomaly⁄birth defect. Each
event is presented using Medical Dictionary for Reg-
ulatory Activities (MedDRA) preferred terms (ver-
sion 10.0) and with causality assessed by the trial
investigator.
Using the DBPC database, incidence of adverse
events, severe and serious adverse events and discon-
tinuations were derived from the double-blind phase
only. Data were analysed by dose (ﬁxed-dose trials)
and by modal ﬂexible-dose (ﬂexible-dose trials).
Modal ﬂexible-dose was deﬁned as the dose the man
was exposed to the longest during the trial period; if
the exposure duration was equal for two different
doses, the higher dose was selected as the modal
dose. Data were also analysed by starting dosage
(< 50, 50 and 100 mg) and by starting dose stratiﬁed
by age groups. In this report, only the data for start-
ing doses of 50 and 100 mg are considered. Death
listings are reported for all phases of the study (e.g.
including open-label extension).
Most postmarketing adverse event reports are sub-
mitted voluntarily, causality is not assessed, clinical
information may be missing or incomplete, follow-
up information may not be available, the magnitude
of underreporting is unknown and many factors
inﬂuence reporting (i.e. length of time since market-
ing, market share of the drug, publicity or media
reports about the drug or an adverse event, the seri-
ousness of an adverse reaction, regulatory actions
and awareness by healthcare professionals and con-
sumers of adverse event reporting and litigation)
(33,34). Furthermore, because the source of medica-
tion is usually not captured, reports related to non-
genuine products can enter a database. For example,
an estimated 44% of tablets labelled ‘Viagra’ and sold
over the Internet is counterfeit (35). Counterfeit
ED medications may contain none or an unknown
quantity of the purported active ingredient, other
possibly active ingredients of unknown efﬁcacy and
safety, or even toxic ingredients (36). Therefore, the
spontaneous reporting system yields reporting rates,
not incidence rates, and it is generally not appropri-
ate to make comparisons between drugs in reporting
rates. The most important role of the spontaneous
reporting system is for signal detection (34).
Common adverse events were deﬁned as those
occurring in > 2% of men in ‡ 1 treatment or age
group in the DBPC database, or at a reporting rate
‡ 1% in at least one of the two dosage groups in the
postmarketing safety database.
Special safety topics
Several safety topics of special interest were selected
for more detailed analysis, including certain adverse
events [e.g. cardiovascular risk, priapism and non-
arteritic anterior ischaemic optic neuropathy
(NAION)] and events that might arise from intrinsic
factors (e.g. impairment of renal and hepatic func-
tion), drug interactions [e.g. with nitrates, cyto-
chrome P3A4 (CYP3A4) inhibitors, concomitant ED
medications and a-blockers] or incorrect use (e.g.
overdose and abuse). Some of these topics (cardio-
vascular risk and impaired renal and hepatic func-
tion) are medical history factors, which are not
coded in the postmarketing safety database and
therefore could not be searched in that database.
Cardiovascular risk was assessed using the DBPC
database, in men with cardiovascular disease, receiv-
ing antihypertensive medications, or with diabetes.
Also using the DBPC database, baseline laboratory
parameters were used to identify moderate renal
impairment (deﬁned as > 1.5 times the upper limit
of normal blood urea nitrogen⁄urea and creatinine)
and moderate hepatic impairment [deﬁned as > 1.5
times the upper limit of normal for ‡ 2 tests, includ-
ing aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase and total
bilirubin]. MedDRA-preferred terms were used to
search for priapism, NAION, hearing loss and incor-
rect use [although cases having the intent to self-
harm (e.g. suicide or suicide attempt) were excluded
from the overdose analysis]. Comprehensive lists of
a-blockers, nitrates, nitric oxide donors, CYP3A4
inhibitors and concomitant ED medications (37)
were used to search for drug interactions.
Results and discussion
Databases
The DBPC database contained more than 14,000
men, who were enrolled and received at least one
dose of study drug. The mean age of sildenaﬁl and
placebo patients in the 54 parallel design trials was
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trends were observed for the 13 cross-over trials.
Most of the men were white. At the time of enrol-
ment ED had persisted, on average, for 4.5 years; it
was most frequently organic in origin. The most
common concomitant illnesses were of cardiovascu-
lar aetiology or associated with cardiovascular risk
factors [i.e. hypertension, diabetes mellitus (non-
insulin dependent), hyperlipidaemia, hypercholeste-
rolaemia, coronary artery disease and a history of
myocardial infarction] reﬂecting the age-related prev-
alence of these conditions. Benign prostatic hyperpla-
sia and localised prostate cancer, treated with
transurethral prostatectomy and radical prostatecto-
my, respectively, were also relatively common, as
were conditions associated with an elderly or ageing
population (e.g. osteoarthritis and visual distur-
bance).
Consistent with a population of advancing age and
with the underlying comorbidity frequently seen in
patients with ED, the most common medications
taken were those used to treat hypertension, hyper-
lipidaemia, diabetes mellitus, arthritic conditions and
skeletal muscular injuries, and to prevent myocardial
infarction. Thus, the DBPC database includes a het-
erogeneous ED population that is representative of
the ED population as a whole.
The postmarketing safety database identiﬁed
39,277 sildenaﬁl patients with adverse events through
July 15, 2007. The vast majority of these were
reported spontaneously by health or non-health pro-
fessionals (Table 1). The ﬁrst daily dose was identi-
ﬁed in slightly less than half of the cases (i.e. > 25
and £ 50 mg, n = 12,843; > 50 and £ 100 mg,
n = 5066). Demographical and case characteristics,
where known, were comparable to those observed for
the DBPC database, in that the majority of the popu-
lation was ‡ 50 years of age and the majority of cases
reported a ﬁrst total daily dose of 25–100 mg. Most
of the cases were non-serious (80.4%) and approxi-
mately half (54%; 21,334⁄39,277) of the men
reported a case outcome. Of the cases with known
case outcomes, nearly half (49%; 10,498⁄21,334)
reported an outcome of recovered⁄recovering⁄recov-
ering with sequelae, and very few reported a fatal
outcome (6.1%; 1303⁄21,334). Medical history is not
a coded search function in the postmarketing safety
database, but concomitant medications were consis-
tent with common concomitant medications used by
men in the DBPC database.
Tolerability of 50 mg vs. 100 mg
The safety proﬁle of sildenaﬁl, based on data from
the DBPC database that included more than 7500
men treated with sildenaﬁl 50 or 100 mg (Tables 2–
4), remained consistent with that presented in the
original regulatory submissions from approximately
10 years ago. Very rare were the serious adverse
events of priapism (n = 11 patients), NAION (n =0
patients) and hearing loss (n = 1 patient of unilat-
eral loss considered to be embolic in aetiology),
which are discussed in detail in subsequent sections
of this review. Common adverse events in men trea-
ted with sildenaﬁl were those related to the pharma-
cology of PDE5 inhibition, such as headache,
vasodilation and facial ﬂushing. These were reported
in a higher incidence of men treated with sildenaﬁl
than with placebo (Table 4) and in a comparable
incidence to that documented in the Viagra product
information leaﬂet (15). Previously reported data
collated from 17 of the randomised, DBPC, ﬂexible-
dose trials showed that the rate of these common
adverse events decreased markedly over a 16-week
treatment period such that, during the ﬁrst
4–6 weeks of treatment, the rate among sildenaﬁl-
treated patients was higher than that for placebo-
treated patients but, by 8 weeks and thereafter, the
rate was similar between sildenaﬁl- and placebo-trea-
ted patients (Figure 1) (38).
The safety proﬁles of sildenaﬁl 50 and 100 mg in
the DBPC trials were comparable, in that there was
no apparent increase in the incidence of men with
all-causality or treatment-related adverse events
among those receiving 100 mg as a ﬁxed or ﬂexible-
dose compared with those receiving 50 mg as a ﬁxed
or ﬂexible-dose (Tables 2 and 4). The exception to
Table 1 Sources of cases populating the postmarketing
safety database
Source Number (%)
Spontaneous
Health professional 15,894 (40.5)
Non-health professional 22,397 (57.0)
Total 38,391 (97.5)
Health authority
Health professional 658 (1.7)
Non-health professional 21 (0.1)
Total 679 (1.7)
Published report 307 (0.8)*
Total 39,277 (100)
*The international literature is carefully screened daily to iden-
tify all relevant cases. Although an attempt is consistently
made to avoid counting events twice, there may be a few
duplicate cases, i.e. reported in observational studies published
in the literature (e.g. the International Men’s Health Study (29)
and Prescription Event Monitoring study (24)) and as spontane-
ous postmarketing cases.
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transient altered colour vision (chromatopsia and
cyanopsia) at doses of ‡ 100 mg (15). Indeed, for
some adverse events, the incidence was higher among
those receiving 50 mg than among those receiving
100 mg. For example, headache [ﬁxed-dose: 14.4%
(50 mg) vs. 12.2% (100 mg); modal ﬂexible-dose:
12.8% (50 mg) vs. 8.8% (100 mg)] and ﬂushing
[ﬁxed-dose: 13.3% (50 mg) vs. 9.5% (100 mg); ﬂexi-
ble-dose: 10.0% (50 mg) vs. 7.8% (100 mg)]
(Table 4). It is likely that the differences between
ﬁxed-doses are clinically meaningless and that those
between ﬂexible-doses reﬂect enrichment of the 50-
mg group with patients having tolerability issues that
prevented dosage increase, such that their most fre-
quent dose throughout the study was 50 mg.
In the population as a whole and in all subgroups
stratiﬁed by age, the overall incidence of men with
adverse events was similar in those initiating treat-
ment with 100 mg vs. 50 mg, except for a slight
dose-related increase in the incidence of treatment-
related adverse events among older men (Table 3).
Among the most common treatment-related adverse
events, the incidence was generally similar with a
starting dose of 100 mg vs. 50 mg (Table 4). The
exception to this was headache in men aged
‡ 75 years, which occurred in 5.4% (2⁄37) of those
starting with 100 mg and in 9.7% (13⁄134) of those
starting with 50 mg. For most events, the incidence
was also similar across age subgroups for each start-
ing dose. Noteworthy exceptions to this were a
higher incidence of men with dyspepsia in the sub-
group of men aged ‡ 75 years, which was relatively
small (50 mg, n = 134; 100 mg, n = 37), and a lower
incidence of men with headache and nasal conges-
tion in the subgroups of men aged ‡ 75 or
‡ 65 years.
The majority of adverse events included in the
postmarketing safety database were known sildenaﬁl
adverse drug reactions, similar to those reported in
DBPC trials. Overall, the onset of more of the
adverse events occurred in association with a total
daily dose of 50 mg [i.e. > 25–50 mg; 32.7%
(12,843⁄39,277)] than with a total daily dose of
100 mg [i.e. > 50–100 mg; 12.9% (5066⁄39,277)].
The higher number of reports in association with a
total daily dose of 50 mg likely reﬂects that most
adverse event reports are generated in men newly on
Table 2 Overview of adverse events and discontinuations stratiﬁed by dose, in 67 double-blind placebo-controlled
trials
Adverse events
Fixed-dose trials Flexible-dose trials
Sildenaﬁl dose Modal sildenaﬁl dose*
50 mg
(N = 804)
100 mg
(N = 1373)
Placebo
(N = 1623)
50 mg
(N = 2060)
100 mg
(N = 3479)
Placebo
(N = 4979)
AE, number of events
All causality 1101 1419 769 1807 2768 2491
Treatment-related 501 781 181 1077 1421 668
AE, number (%) of patients
All causality 498 (61.9) 655 (47.7) 489 (30.1) 951 (46.2) 1549 (44.5) 1572 (31.6)
Severe 51 (6.3) 56 (4.1) 41 (2.5) 87 (4.2) 102 (2.9) 127 (2.6)
Serious 17 (2.1) 19 (1.4) 23 (1.4) 37 (1.8) 55 (2.6) 67 (1.3)
DC 14 (1.7) 20 (1.5) 19 (1.2) 50 (2.4) 27 (0.8) 49 (1.0)
Dose reduction or temporary DC 20 (2.5) 18 (1.3) 17 (1.0) 118 (5.7) 59 (1.7) 68 (1.4)
Treatment-related 295 (36.7) 436 (31.8) 136 (8.4) 655 (32.3) 885 (25.4) 480 (9.6)
Severe 21 (2.6) 19 (1.4) 6 (0.4) 35 (1.7) 29 (0.8) 19 (0.4)
Serious 1 (0.1) 1 (0.1) 1 (0.1) 3 (0.1) 5 (0.1) 3 (0.1)
DC 8 (1.0) 10 (0.7) 7 (0.4) 28 (1.4) 10 (0.3) 18 (0.4)
Dose reductions or temporary DC 1 (0.1) 8 (0.6) 1 (0.1) 102 (5.0) 29 (0.8) 32 (0.6)
AE, adverse event; DC, discontinuation.
*Modal dose: dose the patient was exposed to the longest during the study period. If the duration was the same for two different
doses, the higher dose was selected as the modal dose of the patient.
An event was categorised according to investigator judgment as severe if it interrupted daily activity and required systemic drug therapy
or other medical treatment. A serious adverse event was deﬁned as any untoward medical occurrence that resulted in death, was life
threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, or resulted in a persistent or signiﬁcant
disability⁄incapacity or a congenital anomaly⁄birth defect. Listed are DCs, dose reductions and temporary DCs that were caused by an AE.
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naﬁl staring dose. For most types of events, the
reporting rates were similar between the 50- and
100-mg dose (Table 5). Not listed in Table 5 are
reports of drug ineffective [50 mg, n = 3803
(29.6%); 100 mg, n = 2038 (40.2%)], drug effect
decreased [50 mg, n = 1090 (8.5%); 100 mg, n = 397
(7.8%)], or ED [50 mg, n = 1132 (8.8%); 100 mg,
n = 449 (8.9%)] because the efﬁcacy of sildenaﬁl is
well established (12,13), an increase in dose or sec-
ond-line treatment should be considered in cases in
which sildenaﬁl is ineffective (39), and it is the role
of the healthcare professional to establish realistic
treatment goals and expectations. Most men in
whom sildenaﬁl treatment failed responded success-
fully after re-education and counselling, which
included information on patient and partner expec-
tations, how to properly take the drug, titration to
maximum dose and a minimum trial of eight
attempts (40).
In the DBPC database, the safety proﬁles of silde-
naﬁl 50 and 100 mg were comparable in that there
were no apparent dose-related increases in the inci-
dence of men with severe adverse events, serious
Table 4 Common treatment-related adverse events, stratiﬁed by dose and age, in 67 double-blind placebo-controlled trials
Trial design dosage (n)
Age group (n)
Event by disorder system, number (%) of patients with event [with severe event]*
Eye GI Nervous system Respiratory Vascular
Chromatopsia Cyanopsia
Visual
disturbance Dyspepsia Dizziness Headache
Nasal
congestion Flushing Hot ﬂush
Fixed-dose
Sildenaﬁl 50 mg (804) 4 (0.5) 1 (0.1) 1 (0.1) 35 (4.4) [3] 14 (1.7) [1] 116 (14.4) [9] 15 (1.9) [1] 107 (13.3) [1] 27 (3.4) [1]
Sildenaﬁl 100 mg (1373) 17 (1.2) [1] 19 (1.4) 35 (2.5) 64 (4.7) [6] 18 (1.3) 167 (12.2) [13] 29 (2.1) [1] 130 (9.5) [5] 30 (2.2)
Placebo (1623) 0 1 (0.1) 1 (0.1) 7 (0.4) 9 (0.6) 39 (2.4) [1] 2 (0.1) 16 (1.0) 3 (0.2)
Flexible-dose
Sildenaﬁl 50 mg (2060) 8 (0.4) 14 (0.7) 12 (0.6) 50 (2.4) [6] 58 (2.8) 264 (12.8) [21] 42 (2.0) [3] 205 (10.0) [2] 28 (1.4) [1]
Sildenaﬁl 100 mg (3479) 13 (0.4) 36 (1.0) 23 (0.7) 101 (2.9) [5] 53 (1.5) 305 (8.8) [19] 65 (1.9) [3] 271 (7.8) [4] 12 (0.3)
Placebo (4979) 2 (0) 1 (0) 5 (0.1) 15 (0.3) [1] 40 (0.8) [2] 155 (3.1) [11] 12 (0.2) 65 (1.3) [1] 7 (0.1)
All trials
Sildenaﬁl 50 mg, initial dose
All ages (6207) 24 (0.4) 51 (0.8) 35 (0.6) 181 (2.9) 127 (2.0) 705 (11.4) 125 (2.0) 577 (9.3) 56 (0.9)
< 65 years (5003) 21 (0.4) 42 (0.8) 27 (0.5) 146 (2.9) 103 (2.1) 587 (11.7) 107 (2.1) 472 (9.4) 47 (0.9)
‡ 65 years (1203) 3 (0.2) 9 (0.7) 8 (0.7) 35 (2.9) 24 (2.0) 118 (9.8) 18 (1.5) 105 (8.7) 9 (0.7)
‡ 75 years (134) 1 (0.7) 0 2 (1.5) 9 (6.7) 0 13 (9.7) 1 (0.7) 13 (9.7) 1 (0.7)
Sildenaﬁl 100 mg, initial dose
All ages (1337) 16 (1.2) [1] 19 (1.4) 35 (2.6) 64 (4.8) [6] 18 (1.3) 163 (12.2) [13] 28 (2.1) [1] 124 (9.3) [5] 23 (1.7)
< 65 years (1026) 10 (1.0) [1] 15 (1.5) 32 (3.1) 49 (4.8) [4] 12 (1.2) 134 (13.1) [10] 26 (2.5) [1] 98 (9.6) [5] 18 (1.8)
‡ 65 years (308) 6 (1.9) 4 (1.3) 3 (1.0) 15 (4.9) [2] 6 (1.9) 29 (9.4) [3] 2 (0.6) 26 (8.4) 5 (1.6)
‡ 75 years (37)§ 1 (2.7) 0 1 (2.7) 3 (8.1) 1 (2.7) 2 (5.4) 0 3 (8.1) 1 (2.7)
Placebo
All ages (6602) 2 (0) 2 (0) 6 (0.1) 22 (0.3) [1] 49 (0.7) [2] 194 (2.9) [12] 14 (0.2) 81 (1.2) [1] 10 (0.2)
< 65 years (5294) 2 (0) 2 (0) 3 (0.1) 21 (0.4) [1] 40 (0.8) [1] 161 (3.0) [12] 12 (0.2) 63 (1.2) [1] 9 (0.2)
‡ 65 years (1303) 0 0 3 (0.2) 1 (0.1) 9 (0.7) [1] 33 (2.5) 2 (0.2) 18 (1.4) 1 (0.1)
‡ 75 years (128) 0 0 0 0 0 2 (1.6) 0 1 (0.8) 0
AE, adverse event; DC, discontinuation; GI, gastrointestinal.
*Events occurring in > 2% of men in ‡ 1 group. An event was categorised according to investigator judgment as severe if it interrupted daily activity and required
systemic drug therapy or other medical treatment. Listed are DCs, dose reductions and temporary DCs that were caused by an AE. Severe events are shown only
when ‡ 1 occurred. Because of the small number of severe events, percentages are not given.
In ﬂexible-dose trials, dose is the modal dose, the dose that the patient was exposed to the longest during the study period. If the duration was the same for two
different doses, the higher dose was selected as the modal dose of the patient.
Sum of patient numbers in the ‘< 65 years’ group plus the ‘‡ 65 years group’. do not total the numbers in the ‘All ages’ group because age was missing for one
patient (50 mg) and three patients (100 mg).
§In addition to the tabulated events, there were also 1 (2.4%) case each of iris disorder (mild), abdominal discomfort (mild), diarrhoea haemorrhagic (moderate),
gastroesophageal reﬂux (mild), nausea (mild), fatigue (moderate), heart rate increase (mild), musculoskeletal pain (moderate), pain in extremity (moderate) and
hypoesthenia (mild).
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events or dose reductions caused by adverse events
in the population as a whole (Table 3) and in either
the ﬁxed-dose trials or the ﬂexible-dose trials
(Table 2). Across subgroups stratiﬁed by starting
dose and age, there was a low incidence of men with
treatment-related serious events (< 1%), severe
events (< 2%), discontinuations caused by adverse
events (< 3%) and dose reductions or temporary dis-
continuations caused by adverse events (£ 3%)
(Table 3).
The overall frequency of death was low in the
DBPC database and was comparable between men
using sildenaﬁl (13⁄8691, 0.15%) and placebo
(7⁄6602, 0.11%). Most deaths were in men aged
‡ 50 years. Among the deaths were six men using
50 mg (mean age, 56.8 years), of whom two were
‡ 65 years and one was ‡ 75 years; ﬁve men using
100 mg (mean age, 62.4 years), of whom three
were ‡ 65 years and one was ‡ 75 years; and seven
men using placebo (mean age, 67.2 years), of
whom six were ‡ 65 years and one was ‡ 75 years.
None of the deaths was considered to be treatment
related.
In the postmarketing safety database, approxi-
mately 20% (7683⁄39,277) of patients were consid-
ered serious and 3.3% of patients (1310⁄39,277) had
an outcome of death. Of the 882 deaths for which
age was reported, the majority of cases [79.4%
(700⁄882)] involved patients aged > 50 years. For
serious adverse events and deaths, the order of mag-
nitude differences between the incidence rates of the
DBPC database and the reporting rates of the post-
marketing safety database reﬂects the vastly different
natures of these metrics, as described in Methods
section.
Cardiovascular risk
The prevalence of ED is increased in men at risk for
cardiovascular disease (41–47). Further evidence for
the relationship between ED and cardiovascular dis-
ease is that the most common organic cause of ED is
vascular disease (31,48) and some of the most com-
mon comorbid diagnoses in men with ED are car-
diovascular disease risk factors (i.e. hypertension,
hyperlipidaemia and diabetes mellitus) (49). How-
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Figure 1 Rate of treatment-related adverse events over time
collated from 17 randomised, double-blind, placebo-
controlled, ﬂexible-dose trials (sildenaﬁl 25–100 mg,
n = 2362; placebo, n = 1986). Treatment periods of up to
4 months were divided into 2-week intervals; the number
of patients who experienced any adverse event was
recorded for each interval and divided by the total number
of patients who received treatment during that interval (38)
Table 5 In the postmarketing safety database, reporting
rate of common adverse drug reactions for which the
ﬁrst total daily dose was 50 or 100 mg
Disorder system
Event, n (%)*
First total daily dose
50 mg
N = 12,843
reports
100 mg
N = 5,066
reports
Cardiac
Myocardial infarction 273 (2.1) 95 (1.9)
Palpitation 236 (1.8) 48 (0.9)
Tachycardia 165 (1.3) 36 (0.7)
Eye disorders
Cyanopsia 233 (1.8) 189 (3.7)
Vision blurred 244 (1.9) 89 (1.8)
Visual disturbance 149 (1.2) 74 (1.5)
Gastrointestinal
Dyspepsia 415 (3.2) 174 (3.4)
Nausea 276 (2.2) 82 (1.6)
General and administration site
Chest pain 220 (1.7) 59 (1.2)
Drug interaction 248 (1.9) 121 (2.4)
Feeling hot 202 (1.6) 47 (0.9)
Malaise 130 (1.0) 40 (0.8)
Injury, poisoning and procedural complications
Intentional drug misuse 85 (0.7) 66 (1.3)
Intentional overdose 153 (1.2) 121 (2.4)
Overdose 154 (1.2) 65 (1.3)
Nervous system
Dizziness 502 (3.9) 167 (3.3)
Headache 1929 (15.0) 574 (11.3)
Reproductive system
Priapism and related events 305 (2.4) 132 (2.6)
Respiratory
Dyspnoea 163 (1.3) 54 (1.1)
Nasal congestion 530 (4.1) 156 (3.1)
Skin and subcutaneous tissue
Erythema 304 (2.4) 59 (1.2)
Vascular
Flushing 1367 (10.6) 409 (8.1)
Hot ﬂush 183 (1.4) 26 (0.5)
*Events constituting ‡ 1% of reported events in ‡ 1o ft h e
two dosage groups are listed.
50 mg = > 25–50 mg; 100 mg = > 50–100 mg.
Priapism and erection increased.
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that sildenaﬁl use was associated with increased risk
of adverse cardiovascular disease events (27,29,50–
52).
Not surprisingly, given the known association
between ED and cardiovascular disease, and between
age and cardiovascular disease, the most commonly
reported adverse events that resulted in death in the
DBPC database were cardiac related (i.e. myocardial
infarction, cardiac arrest, cardiac failure and coro-
nary artery disease), and most of these were in men
aged ‡ 50 years. However, it should be noted that
the deaths were not attributed to sildenaﬁl and that
the overall cardiovascular death rate was slightly
higher in the placebo groups (3 of 7 deaths) than in
the sildenaﬁl groups (4 of 11 deaths). Similarly, the
incidence of men with serious cardiovascular events
was comparable and not signiﬁcantly different in the
sildenaﬁl and placebo groups [i.e. acute myocardial
infarction (4.1% vs. 4.5%), chest pain (3.0% vs.
2.3%), coronary artery disease (2.7% vs. 5.3%), myo-
cardial infarction (2.5% vs. 3.8%) and cerebrovascu-
lar accident (2.5% vs. 2.3%)], and none of these
serious cardiovascular events was related to sildenaﬁl
treatment.
Based on available safety data, there is no evidence
of a causal link between sildenaﬁl and cardiovascular
events. Safety data from the original regulatory sub-
missions, postmarketing observational studies (24,29)
and published literature demonstrate that sildenaﬁl
does not increase the rate of myocardial infarction or
other serious cardiovascular events in men with ED.
Furthermore, the safety proﬁle of sildenaﬁl in men
with ED and diabetes mellitus (11,53,54), arterial
hypertension (55) or cardiovascular conditions
(56,57) is similar to that in men with ED without
these conditions. The safety of sildenaﬁl has not been
studied in men with hypotension (blood pressure
<9 0⁄50 mmHg) or recent history of stroke or myo-
cardial infarction, and its use is therefore currently
contraindicated in men with these conditions (15).
Priapism
Priapism is a rare adverse drug reaction with sildena-
ﬁl. In the DBPC database, the incidence of men with
priapism or related events was 0.1% (11⁄8691) in
sildenaﬁl recipients and < 0.1% (2⁄6602) in placebo
recipients. Most cases reported events that were con-
sidered mild in severity; none that was considered as
severe or deﬁned as serious; and most of which
resolved with no action, intervention or reduction of
dose. Eight of the cases were associated with sildena-
ﬁl 50 mg, including two that were characterised by
multiple events and two (one of which resolved with
a dose reduction) that were characterised by a
duration of > 1 day. Three of the cases were associ-
ated with sildenaﬁl 100 mg, including two that were
characterised by multiple events that resolved, and
two that were characterised by a duration of > 1 day
and resolved with no action.
The postmarketing safety database was searched
for priapism-related events (coded in the MedDRA
as ‘priapism’ and ‘erection increased’). Comparison
of priapism-related events as reported by healthcare
professionals and consumers, respectively, shows
that, although the same pathological entity gets
reported (in most cases as a serious event), reports
of healthcare professionals tend to use the term ‘pri-
apism,’ whereas those of consumers tend to use the
term ‘erection increased.’ The reporting rate was
2.5% for sildenaﬁl 50 mg (320⁄12,843 total patients)
and 2.7% for sildenaﬁl 100 mg (138⁄5066 total
patients). In contrast to the DBPC database, for
which none of the cases of priapism was considered
by the investigator to be severe or fulﬁlled the deﬁni-
tion for ‘serious’, 56% (180⁄320) of the reports in
the postmarketing safety database that were associ-
ated with sildenaﬁl 50 mg and 64% (89⁄138) of the
reports in the postmarketing safety database that
were associated with sildenaﬁl 100 mg were reported
as serious events. However, for most of the priapism
cases, the reporter indicated that the case was not
clinically severe. Also, for most of the priapism cases,
the reporter indicated that the patient had recovered
or was recovering without sequelae at the time of the
report.
The risk of priapism appears to be increased in
certain situations. For example, in cases of sildenaﬁl
overdose, priapism was reported at a rate more than
twice that of the overall postmarketing safety data-
base. Also, across all sildenaﬁl doses, concomitant
medication use was reported in 377 reports of pria-
pism, in 27% (102⁄377) of which the concomitant
medication(s) could have contributed to the pria-
pism [i.e. other ED medications, alpha-adrenergic
antagonists (phentolamine), psychotropics (amitrip-
tyline, nortriptyline, trazodone, ﬂuphenazine),
amphetamines and cocaine]. In the subgroup of cases
that reported concomitant use of another ED medi-
cation, alprostadil was used concomitantly with silde-
naﬁl in 74% (14⁄19) of the patients of priapism.
As priapism, although rare, is a potentially serious
adverse event, the Viagra summary of product char-
acteristics (SmPC) recommends use with caution in
patients with anatomic deformation of the penis or
in patients who have conditions that may predispose
them to priapism (such as sickle cell anaemia, multi-
ple myeloma or leukaemia) (15). Interestingly, silde-
naﬁl has been reported to be successful in relieving
priapism in patients with sickle cell disease (58).
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Events suggestive of NAION were not discovered in
the DBPC database. In the postmarketing safety data-
base, the reporting rate for events suggestive of
NAION was 0.8% (333⁄39,277). Nearly half (48%)
of the cases for which medical history or concomi-
tant medication information was available reported
possible predisposing risk factors, including previous
ocular disorders (n = 52), hypertension (n = 58), hy-
perlipidaemia (n = 47), diabetes mellitus and related
conditions (n = 29), smoking (n = 36) and coronary
artery disease (n = 21). More than half of the events
suggestive of NAION were reported by attorneys
rather than healthcare professionals and lack appro-
priate medical information.
No cases of NAION were discovered in a
retrospective review of > 13,000 patients in the
manufacturer’s clinical trials database or during 2935
patient-years of follow up in a prospective observa-
tional study of 3813 men (mean age, 57 years) (59).
In another prospective observational study, one case
of NAION was identiﬁed in a total of 35,569 patient-
years of observation, representing an unadjusted
NAION incidence estimated to be 2.8 patients per
100,000 patient-years of exposure to sildenaﬁl, which
is similar to or lower than estimates in general popu-
lation samples (59).
The data cited herein do not suggest an increased
incidence of NAION in men who took sildenaﬁl for
their ED. However, because a causal association
between visual ﬁeld defects and NAION has not been
excluded, sildenaﬁl is contraindicated in patients
who have loss of vision in one eye because of
NAION, regardless of whether this episode was
related to previous exposure to a PDE5 inhibitor
(15). Should a sudden visual defect occur, the patient
should stop taking sildenaﬁl and consult a physician
immediately (15).
Hearing loss
In the DBPC database, events of hearing loss were
limited to one case of severe unilateral deafness
which is considered to be embolic in aetiology and
unrelated to sildenaﬁl treatment and a case of mild
deafness that was related to sildenaﬁl treatment. In
the latter case, the event is reported as ‘exacerba-
tion of hearing loss,’ implying a relevant medical
history, and the patient had concurrent multiple
sclerosis.
In the postmarketing safety database, reports were
extremely rare, with a reporting rate of 0.01%
(3⁄39,277) for sudden hearing loss and 0.07%
(26⁄39,277) for impaired hearing. The one literature
case report in a patient with ED indicated emergence
of the event shortly after dosing. This report appears
to be isolated, and critical information around dos-
ing and patient characteristics is omitted (60).
Hearing loss is a prevalent condition in the general
population and is associated with a number of
underlying risk factors, including several drugs. The
pharmacological action of sildenaﬁl is not consistent
with known ototoxic mechanisms, and there have
been no cases that demonstrate the absence of
known risk factors and clear evidence of sildenaﬁl
challenge⁄dechallenge or dosing in relation to onset.
Impaired renal function and hepatic function
Medical history is not a search function that is coded
in the postmarketing safety database, but the DBPC
database was searched for safety data in men with
ED and moderate impairment of renal or hepatic
function.
Sildenaﬁl has a low renal clearance (< 2%) and
excretion because of high tubular reabsorption in the
kidney. Sildenaﬁl is excreted as metabolites predomi-
nantly in the faeces (approximately 80% of adminis-
tered oral dose) and to a lesser extent in the urine
(approximately 13% of administered oral dose) (61).
In the DBPC database, the sildenaﬁl safety proﬁle in
the 21 men with moderate impairment of renal func-
tion was similar to that in men with ED and no
impairment of renal function. None had a worsening
of blood urea nitrogen⁄urea or creatinine values, and
only 2 of 7 (29%) randomised to sildenaﬁl and 9 of
14 (64%) randomised to placebo had adverse events.
The adverse events in the two sildenaﬁl recipients
(moderate abdominal pain and sciatica; mild periph-
eral oedema) were not related to sildenaﬁl treatment.
Furthermore, published literature suggests that silde-
naﬁl is well tolerated in men with ED and receiving
dialysis (62), chronic dialysis (63), haemodialysis
(64) and peritoneal dialysis (65); across these pub-
lished trials, in which a total of 86 men received sil-
denaﬁl, the most common adverse events were
similar in frequency, nature and severity to those
observed in patients without renal impairment (i.e.
headache, ﬂushing, visual disturbances, hypertension,
nasal congestion and dyspepsia). Thus, results from
approximately 100 men treated with sildenaﬁl in the
DBPC database and the published literature suggest
that sildenaﬁl is well tolerated in patients with mod-
erate renal impairment. As sildenaﬁl clearance is
reduced in patients with severe renal impairment
(creatinine clearance < 30 ml⁄min), a 25-mg initial
dose should be considered; based on efﬁcacy and tol-
eration, the dose may be increased to 50 or 100 mg
(15).
Sildenaﬁl is extensively and rapidly metabolised by
the liver, primarily by CYP3A4 enzymes (15). In
men with moderate impairment of hepatic function,
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ﬁle that was similar to that in men with ED and no
impairment of hepatic function. Of the 26 men in
the DBPC database who had moderate hepatic
impairment and were treated with sildenaﬁl, 23%
(6⁄25) experienced a worsening of their alkaline
phosphatase, AST, ALT or total bilirubin values,
none of which was attributed to sildenaﬁl. Adverse
events were experienced by 77% (20⁄26) of the silde-
naﬁl recipients with hepatic impairment compared
with 37% (7⁄19) of the placebo patients with hepatic
impairment. In these men, all of the adverse events
that were attributed to sildenaﬁl treatment were mild
in severity. As sildenaﬁl clearance is reduced in men
with hepatic impairment (e.g. cirrhosis), a 25-mg ini-
tial dose should be considered; based on efﬁcacy and
toleration, the dose may be increased to 50 or
100 mg (15). The safety of sildenaﬁl has not been
studied in men with severe hepatic impairment, and
its use is therefore contraindicated (15).
Drug interactions
As sildenaﬁl potentiates the hypotensive effects of
nitrates, its concomitant administration with nitric
oxide donors (such as amyl nitrite) or nitrates in any
form is contraindicated (15). Drug interaction stud-
ies have shown that concomitant administration of
sildenaﬁl and nitrates is associated with known
sildenaﬁl adverse drug reactions (mainly class effects
associated with PDE5 inhibition) and consistent
reductions in blood pressure (18). Very few men in
the DBPC database took nitrates concomitantly with
sildenaﬁl (16⁄8691) or placebo (9⁄6602), and none
of these reported hypotension as an adverse event.
Treatment-related adverse events were limited to one
man treated with 50 mg who had dyspepsia and one
man treated with 100 mg who had periorbital
swelling, severe headache and facial ﬂushing. In the
postmarketing safety database, concomitant nitrate
use represented approximately 1% (478⁄39,277) of
patients, and the most frequent associated adverse
events were consistent with the underlying cardiovas-
cular conditions treated by nitrates [e.g. myocardial
infarction (18%) and chest pain (15%)] or were
hypotensive events from the known pharmacody-
namic interaction of sildenaﬁl and nitrates (11%).
Sildenaﬁl metabolism is principally mediated by
the CYP450 isoforms 3A4 (major route) and 2C9
(minor route); sildenaﬁl clearance is reduced when
administered concomitantly with CYP3A4 inhibitors
such as ketoconazole, erythromycin and cimetidine.
Concomitant administration of a single 100 mg dose
of sildenaﬁl with ritonavir (an HIV protease inhibi-
tor that is a highly potent P450 inhibitor) at steady
state (500 mg twice daily) resulted in increases of
300% (4-fold) in the sildenaﬁl maximum serum con-
centration and 1000% (11-fold) in the sildenaﬁl area
under the plasma concentration vs. time curve (15).
In the DBPC database, a small number of men took
a CYP3A4 inhibitor, most commonly erythromycin
or cimetidine, concomitantly with sildenaﬁl
(67⁄8691) or placebo (43⁄6602). In this subgroup,
treatment-related adverse events occurred in nine
men taking sildenaﬁl 50 mg and in 11 men taking
sildenaﬁl 100 mg, including one man who had treat-
ment-related adverse events at each dose. Treatment-
related adverse events were generally known sildenaﬁl
adverse drug reactions that occurred at a slightly
higher incidence than in the placebo group or in
the entire DBPC database. There were too few post-
marketing cases (n = 19) of concomitant CYP3A4
inhibitor and sildenaﬁl use to make an assessment.
Although the Viagra SmPC advises against the con-
comitant administration of sildenaﬁl with ritonavir
and recommends considering a sildenaﬁl starting
dose of 25 mg when administered concomitantly
with other CYP3A4 inhibitors (15), this collated data
review suggests little difference in the safety proﬁle
of sildenaﬁl across doses (25–100 mg) when adminis-
tered concomitantly with CYP3A4 inhibitors.
The current Viagra SmPC advises that patients
should be haemodynamically stable on a-blocker
therapy before initiating sildenaﬁl treatment, and that
initiation of sildenaﬁl at lower doses (25 mg) should
be considered (to minimise the potential for develop-
ing postural hypotension) (15). The safety of sildena-
ﬁl administered concomitantly with a-blockers was
investigated in three randomised, double-blind, pla-
cebo-controlled, cross-over drug interaction trials
summarised in the SmPC, in which administration of
sildenaﬁl to men with benign prostatic hyperplasia
and stabilised on the non-selective a-blocker doxazo-
sin (4 and 8 mg) was associated with mean additional
supine blood pressure reductions of 7⁄7 mmHg
(25 mg dose), 9⁄5 mmHg (50 mg dose) and
8⁄4 mmHg (100 mg dose) respectively, and with
mean additional standing blood pressure reductions
of 6⁄6 mmHg (25 mg dose), 11⁄4 mmHg (50 mg
dose) and 4⁄5 mmHg (100 mg dose) respectively, but
with infrequent reports of symptomatic postural
hypotension, which included dizziness and light-
headedness, but not syncope) (15). These trials
assessed men aged 35–75 years who had documented
benign prostatic hyperplasia, had been receiving dox-
azosin for at least 2 months and took sildenaﬁl after
they had taken doxazosin 4 mg once daily for 2 weeks
(66). In the ﬁrst trial, one of four men who took
sildenaﬁl 100 mg had a serious adverse event of
postural hypotension that began 35 min postdose and
lasted for 8 h, but none of the 17 men who took
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hypotension. In the second trial, one of 20 men dis-
continued prematurely because of hypotension after
taking sildenaﬁl 50 mg, but he was also taking
minoxidil concomitantly; two other men experienced
hypotension as a moderately severe adverse event,
with onset 1 h after taking sildenaﬁl 50 mg and reso-
lution of hypotension after 7.5 h. In the third trial,
one of 25 men screened with open-label sildenaﬁl
50 mg was discontinued because of symptomatic
hypotension (a moderately severe adverse event)
30 min postdose, but none of the 20 men who took
sildenaﬁl 100 mg during the trial had a severe adverse
event related to blood pressure. In addition to these
single-dose, drug interaction trials, several published
reports of data from randomised, clinical trials
have assessed the safety of sildenaﬁl administered
concomitantly with a-blocker therapy and found no
evidence of symptomatic postural hypotension
associated with concomitant tamsulosin (n = 93) or
terazosin (n = 78) therapy (67), doxazosin therapy
(n = 14) (68) or alfuzosin therapy (n = 21) (69).
In the DBPC database, concomitant a-blocker and
study drug administration was uncommon, occurring
in only 4.2% (368⁄8691) of sildenaﬁl recipients and
5.0% (329⁄6602) of placebo patients. It was also
infrequent in the postmarketing safety database,
occurring in 4.1% (1600⁄39,277) of patients. In both
databases, non-selective a-blocker use (e.g. doxazosin
or terazosin) was reported in most cases. In the
DBPC database, the most commonly reported
adverse events in sildenaﬁl recipients administered
a-blockers concomitantly were dyspepsia, headache
and ﬂushing, which are known adverse drug reac-
tions with sildenaﬁl treatment. The incidence of
events expected from a pharmacological interaction
between sildenaﬁl and an a-blocker (decreased blood
pressure, orthostatic hypotension) was very low, and
there were no cases of hypotension. Adverse events
were similar between men using sildenaﬁl 50 and
100 mg, except for a greater incidence of ﬂushing,
dyspepsia and nasopharyngitis in the latter. Of silde-
naﬁl recipients with adverse events, 46% (168⁄349)
had treatment-related adverse events, mostly mild
events [80% (134⁄168) mild; 1.8% (3⁄168) severe].
In comparison, 16.9% (32⁄189) of placebo patients
who were taking an a-blocker had an adverse event
that was treatment related, of which 9.4% (3⁄32)
were severe. Overall, sildenaﬁl appears to be well tol-
erated by men receiving concomitant a-blockers.
This collated data review suggests little difference in
the safety proﬁle of sildenaﬁl across doses (25–
100 mg) with concomitant use of a-blockers.
Guidelines on the treatment of ED recommend
PDE5 inhibitors as a ﬁrst-line treatment (39,70).
Other treatments include apomorphine sulphate,
vacuum devices, intracavernosal injection with pros-
taglandin E1 and intraurethral delivery of prostaglan-
din E1. The safety proﬁle of sildenaﬁl administered
concomitantly with other ED treatments has not
been investigated in clinical trials and, in the DBPC
database, few men used other ED medications con-
comitantly with sildenaﬁl (13⁄8691) or placebo
(12⁄6602). Treatment-related events, all of which
resolved, occurred in three of these men: mild dys-
pepsia (alprostadil concomitantly with sildenaﬁl
25 mg), mild chromatopsia and headache (alprosta-
dil concomitantly with sildenaﬁl 50 mg and then
100 mg) and moderate atypical chest pain (sildenaﬁl
concomitantly with sildenaﬁl 100 mg). In the post-
marketing safety database, 1.7% (670⁄39,277) of all
patients reported concomitant ED medications;
approved PDE5 inhibitors in more than half and
alprostadil in one-third. In the subgroup that
reported concomitant ED medications, the adverse
events that occurred at more than twice the rate
found in the overall postmarketing safety database
usually represented the known dose-related increase
in visual effects associated with PDE5 inhibition
(cyanopsia and visual disturbance) or a synergistic
pharmacological effect on the penis (erection
increased, penis disorder and priapism). In most
(22⁄40; 55%) of the patients with visual effects,
another PDE5 inhibitor was used concomitantly, and
in most (14⁄19; 74%) of the patients with priapism,
alprostadil was used concomitantly. Other events that
occurred at more than twice the rate found in the
overall postmarketing safety database were related to
underlying medical conditions (e.g. pain, dyspnoea
and increased blood cholesterol and blood pressure)
or to alprostadil injection (e.g. pain). Although the
concomitant use of sildenaﬁl with other treatments
for ED is advised against in the Viagra SmPC (15),
this collated data review identiﬁed no unexpected
adverse drug reactions, suggesting that the safety risk
is likely to be low in the general ED population.
Overdose
Overdose results from intentionally or inadvertently
exceeding the maximum recommended daily dose or
dosing frequency of a drug, which for sildenaﬁl is a
daily dose of 100 mg and (even if the total daily dose
does not exceed 100 mg) a dosing frequency of not
more than once per day. Sildenaﬁl has low general
toxicity; no relevant reproductive toxicity, genotoxic-
ity or carcinogenic properties; and a substantial
safety margin (18,71). Clinical studies of doses higher
than the approved maximum showed an increased
frequency and severity of known adverse drug reac-
tions, including a dose-related increase in the
Safety of sildenaﬁl 251
ª 2009 Blackwell Publishing Ltd Int J Clin Pract, January 2010, 64, 2, 240–255frequency of visual adverse events, but no clear rela-
tionship between dose and maximum decreases in
blood pressure and no clinically signiﬁcant changes
in electrocardiograms (18). With administration
more frequently than once a day, there was an
increased frequency of muscular ache, which was
transient and without evidence of muscular damage,
and dyspepsia (15,18). In the DBPC database, there
were no reports of sildenaﬁl overdose. In the post-
marketing safety database, excluding cases in con-
junction with suicides or suicide attempts, the
reporting rate for sildenaﬁl overdose was 2.3%
(884⁄39,203).
Adverse events in the postmarketing cases of over-
dose were generally known sildenaﬁl adverse drug
reactions (i.e. headache and ﬂushing), which were
generally reported at a slightly higher frequency than
in the overall postmarketing safety database. Pria-
pism was reported at a rate more than twice that of
the overall postmarketing safety database. Of the 884
patients with overdose identiﬁed in the postmarket-
ing safety database, 165 reported a ﬁrst total daily
dose > 100 mg. In this subset, the reporting rate was
more than twice that for the overall postmarketing
safety database for acute myocardial infarction (3.0%
vs. 0.7%), myocardial infarction (6.1% vs. 2.5%),
tachycardia (2.4% vs. 1.0%), drug interaction (4.8%
vs. 2.4%), malaise (2.4% vs. 1.0%), dyspnoea (2.4%
vs. 1.0%) and hypotension (5.5% vs. 1.1%).
Although a relationship with sildenaﬁl overdose can-
not be excluded in 4 of the 12 patients with myocar-
dial infarction and in 14 of the 57 deaths, neither
can a relationship between overdose and increased
cardiac risk be assumed based on the small number
of postmarketing cases. However, we recommend
admission to hospital and cardiac monitoring, pref-
erably in a coronary care unit, for 48 h. In this way,
any cardiovascular complication can be addressed by
experienced healthcare professionals. Standard sup-
portive measures should be adopted as required, but
renal dialysis is not expected to accelerate clearance
because sildenaﬁl is highly bound to plasma proteins
and is not eliminated in the urine.
The highest ﬁrst total daily dose reported was
2400 mg in a 33-year-old man who took 24 tablets
of sildenaﬁl 100 mg. He was diagnosed with annular
scotoma, defective colour vision, vascular retinal
dilatation, visual ﬁeld defect and papilloedema. He
recovered from all events except for visual ﬁeld
defect and annular scotoma.
Thus, the collated data review determined that
overdose with sildenaﬁl is rare in the ED population
and identiﬁed no new safety issues or adverse reac-
tions in conjunction with overdose. It is noteworthy
that, in a parallel-group, double-blind, randomised
trial and its long-term open-label extension study,
the safety proﬁle of sildenaﬁl, in doses up to
240 mg⁄day for the treatment of pulmonary arterial
hypertension, was unchanged compared with lower
dosages (72). In single-dose volunteer studies of
doses up to 800 mg, adverse reactions were similar
to those seen at lower doses, but the incidence rates
and severities were increased (15).
Extensive data (clinical trial data from > 13,000
patients (50,51), 7 years of international postmarket-
ing data, observational studies of > 28,000 men in
the United Kingdom (24) and 3813 men in the
European Union (73)) was used to support the pre-
viously published conclusion that there are no special
cardiovascular concerns when sildenaﬁl is used in
accordance with product labelling (27).
Abuse
Abuse can be classiﬁed as addiction⁄dependence (an
involuntary compulsion, which is usually marked by
tolerance to the effects and withdrawal symptoms
when use is terminated), abuse (recreational use
without medical rationale but without addiction or
dependence) and misuse (intentional or uninten-
tional incorrect use by a healthcare provider or
patient). Unintentional misuse includes accidental
exposure, drug administration error, incorrect dose
administered and medication error. Events relating
to addiction⁄dependence, abuse or misuse of sildena-
ﬁl were not identiﬁed in the DBPC database, but
were identiﬁed in the postmarketing safety database.
The mode of action of sildenaﬁl is peripheral
rather than central (71,74). Consequently, sildenaﬁl
lacks the libido-stimulating activity that classically
deﬁnes an aphrodisiac agent. In addition, there is no
evidence that men with ED develop physical depen-
dence or tolerance to sildenaﬁl. The absence of evi-
dence of tolerance developing to the erectogenic
effects of sildenaﬁl is further supported by the results
of a long-term study over 4 years (75). However, in
the postmarketing safety database, sildenaﬁl depen-
dence was reported in a few [0.15% (58⁄39,277)]
patients, mostly psychological dependence on silde-
naﬁl to achieve erection or insecurity in initiating
intercourse without sildenaﬁl.
Sildenaﬁl abuse represented 0.11% (42⁄39,277) of
all reported events, in 76% of which the patient did
not have a diagnosis of ED. Intentional misuse was
identiﬁed in 1.4% (535⁄39,277) of all patients, most
commonly taking sildenaﬁl for recreational purposes,
without a prescription, and⁄or without a diagnosis
of ED (n = 207) and adjusting the dose or route⁄-
form of administration without direction of a physi-
cian (n = 141). Unintentional misuse was identiﬁed
in 0.91% (357⁄39,277) of patients, including patients
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more of the drug than intended or altered their dose
or dosing frequency without ﬁrst consulting a physi-
cian.
Thus, in the postmarketing safety database, the
predominant form of improper use was obtaining
sildenaﬁl without a prescription and⁄or taking silde-
naﬁl without a diagnosis of ED. Sildenaﬁl is often
obtained through uncontrolled channels outside of
the healthcare system, a risky behaviour that is a
medical concern that needs to be addressed (76–78).
Also, some men take sildenaﬁl for what they perceive
as a better sexual performance, even though they do
not have ED. No new safety signals or emerging
trends were identiﬁed from this review of cases
reporting sildenaﬁl dependence, abuse and misuse.
Conclusions
This collated data review found that sildenaﬁl was
well tolerated at a dose of 50 or 100 mg, overall, in
men who were aged ‡ 65 years and in those who
were aged ‡ 75 years. No causal link was identiﬁed
between sildenaﬁl administered in accordance with
product labelling and cardiovascular events, and fur-
ther support was lent to the safety of sildenaﬁl in
men at risk for cardiovascular disease, in that no
new safety risks relating to cardiovascular events were
identiﬁed in patients with cardiovascular conditions,
hypertension or diabetes mellitus. No new safety
risks were identiﬁed with sildenaﬁl relating to pria-
pism or NAION. In the small number of men with
ED and moderate impairment of renal function or
hepatic function who have been treated with sildena-
ﬁl in DBPC trials, the sildenaﬁl safety proﬁle was
similar to that in men with ED and no impairment
of renal or hepatic function. As sildenaﬁl was well
tolerated, has a relatively short half-life (4–5 h) and
is administered as needed in a maximum of one dose
per day, the safety risk from drug interactions is
likely to be low in the general ED population.
Indeed, no unexpected adverse drug reactions were
identiﬁed from the concomitant use of sildenaﬁl with
nitrates, nitric oxide donors, CYP3A4 inhibitors,
other ED medications or a-blockers. Overdose with
sildenaﬁl was rare in the ED population, and no new
adverse reactions were identiﬁed in conjunction with
overdose, dependence, abuse or misuse. It can be
concluded that sildenaﬁl in all registered doses has a
good safety proﬁle.
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